A recent study has analyzed the relationship between different air pollutants and the main subtypes of lung cancer.

Sacituzumab tirumotecan significantly reduced progression or death risk by 51% compared to chemotherapy in EGFR-mutated non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors. The ...

Thanks to recent therapy advances, the lung cancer mortality rate has declined and survival rates have improved. Many factors influence the likelihood of a lung cancer cure or long-term survival, ...

Researchers found better detection, treatment and decreased smoking have been immensely helpful in reducing deaths due to ...

Ateganosine combined with Libtayo shows improved progression-free survival in advanced non-small cell lung cancer, suggesting potential long-term use. Spevatamig, a bispecific antibody, is being ...

year survival rates averaged across all cancers have never been higher, with 7-in-10 cancer patients living past 5 years post-diagnosis.